Investors Purchase High Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw unusually large options trading activity on Tuesday. Investors acquired 17,427 put options on the company. This is an increase of 207% compared to the average volume of 5,683 put options.

Capricor Therapeutics Trading Up 2.7%

Shares of CAPR stock traded up $0.15 during mid-day trading on Tuesday, reaching $5.71. The stock had a trading volume of 940,060 shares, compared to its average volume of 1,833,013. The firm has a market capitalization of $261.04 million, a PE ratio of -3.50 and a beta of 0.57. The stock’s 50-day moving average price is $6.56 and its two-hundred day moving average price is $8.32. Capricor Therapeutics has a 52-week low of $5.43 and a 52-week high of $20.75.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). On average, equities research analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Octagon Capital Advisors LP bought a new stake in shares of Capricor Therapeutics in the first quarter worth $4,270,000. GSA Capital Partners LLP bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $1,555,000. Jump Financial LLC bought a new stake in Capricor Therapeutics during the first quarter valued at approximately $1,547,000. Goldman Sachs Group Inc. raised its position in Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of Capricor Therapeutics by 15.8% during the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after acquiring an additional 99,384 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CAPR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Wednesday, October 8th. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a report on Thursday, September 25th. Finally, Roth Capital reduced their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $22.25.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.